(Q24246577)

1

0 references

Jane Marjoribanks

2

0 references

Anne Lethaby

3

0 references

Quirine Lamberts

5

object named as

Quirine Lamberts

0 references

author name string

Jane A Suckling

Cochrane Database of Systematic Reviews

4

0 references

publication date

20 July 2005

0 references

published in

0 references

cites work

Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Postmenopausal hormone therapy and change in mammographic density

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Effect of oral postmenopausal hormone replacement on progression of atherosclerosis : a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Treatment of postmenopausal osteoporosis with transdermal estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Unopposed estradiol therapy in postmenopausal women: results from two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Hormone replacement therapy: discrepancies between evidence and recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

Short-term menopausal hormone therapy for symptom relief: an updated decision model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

The WHI estrogen-alone trial--do things look any better?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Estrogen plus progestin and risk of venous thrombosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effect of estrogen therapy on gallbladder disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Local oestrogen for vaginal atrophy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Rationale, design, and conduct of the PEPI Trial. Postmenopausal Estrogen/Progestin Interventions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Baseline characteristics of the PEPI participants. Postmenopausal Estrogen/Progestin Interventions.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Hot flashes: phenomenology, quality of life, and search for treatment options

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: the Women's Angiographic Vitamin & Estrogen Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757].

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757].

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Estrogen replacement therapy, atherosclerosis, and vascular function

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Evidence from randomised trials on the long-term effects of hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Breast cancer and hormone-replacement therapy in the Million Women Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Breast cancer and hormone-replacement therapy: the Million Women Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Menopausal hormone therapy after breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

1 reference

7 January 2021

Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Women's angiographic vitamin and estrogen trial: design and methods

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Design of the Women’s Health Initiative Clinical Trial and Observational Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

A prospective, randomized, placebo-controlled study of the dose effect of oral oestradiol on menopausal symptoms, psychological well being, and quality of life in postmenopausal Chinese women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women; a 5 year randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

The Women's Health Initiative recruitment methods and results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

The women's health initiative postmenopausal hormone trials: overview and baseline characteristics of participants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Estrogen after ischemic stroke: clinical basis and design of the Women's Estrogen for Stroke Trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Women's health initiative. Why now? What is it? What's new?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

The effects of oophorectomy and long-term mestranol therapy on the serum lipids of middle-aged women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

The EWA (estrogen in women with atherosclerosis) study: a randomized study of the use of hormone replacement therapy in women with angiographically verified coronary artery disease. Characteristics of the study population. Effects on lipids and lipo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

A clinical trial of estrogen-replacement therapy after ischemic stroke

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of estrogen plus progestin on health-related quality of life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Estrogen plus progestin and the risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Estrogen plus progestin and colorectal cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Postmenopausal hormones--therapy for symptoms only

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

The ERA trial: findings and implications for the future.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Hormone replacement therapy (HRT)--risks and benefits

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Increased risk of recurrence after hormone replacement therapy in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Estrogen Replacement Therapy II: A Prospective Study in the Relationship to Carcinoma and Cardiovascular and Metabolic Problems

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Esterified estrogen therapy in postmenopausal women. Relationships of bone marker changes and plasma estradiol to BMD changes: a two-year study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Hot flushes during the menopause transition: a longitudinal study in Australian-born women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Climacteric vasomotor symptoms do not imply autonomic dysfunction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Hormone replacement therapy, heart disease, and other considerations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Combined versus sequential hormonal replacement therapy: a double-blind, placebo-controlled study on quality of life-related outcome measures.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of conjugated equine estrogen on stroke in the Women's Health Initiative

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of combination estrogen plus progestin hormone treatment on cognition and affect

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

A practical guide to prescribing hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effect of hormone replacement therapy on self-reported cognitive symptoms: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021

Effects of long-term transdermal administration of estradiol on serum lipids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004143.PUB2

7 January 2021